Main clinical trials of ADCs in endometrial and cervical cancer
| Target | ADC | Trial | Phase | Setting | Treatment | Primary endpoint | Results |
|---|---|---|---|---|---|---|---|
| HER2 | T-DM1 | NCT02675829 [83] | II | HER2 pos tumors including endometrial cancer | T-DM1 | ORR | ORR: 22% |
| NCT02465060 [84] | II | HER2 pos including endometrial and ovarian cancer | T-DM1 | ORR | ORR: 9% | ||
| FRα | Mirvetuximab soravtansine | NCT01609556 [60] | I | FRα pos tumors including metastatic endometrial cancer | Mirvetuximab soravtansine | MTD/RP2D | ORR: 0% |
| Trop2 | Sacituzumab govitecan | IMMU-132-01(NCT01631552) [85] | I/II | Advanced epithelial cancer including endometrial, cervical and ovarian cancer | Sacituzumab govitecan | Safety (phase I)ORR (phase II) | ORR: 22.2% |
| TF | Tisotumab vedotin | InnovaTV 204(NCT03438396) [86] | II | Previously treated recurrent or metastatic cervical cancer | Tisotumab vedotin | ORR | ORR: 24%PFS: 4.2 months |
| InnovaTV 205(NCT03786081) [87] | I/II | Recurrent or metastatic cervical cancer, first line | Tisotumab vedotin + carboplatin | DLT (phase I)ORR (phase II) | ORR: 55%PFS: 9.5 months | ||
| Recurrent or metastatic cervical cancer, second or third line | Tisotumab vedotin + pembrolizumab | DLT (phase I)ORR (phase II) | ORR: 38%PFS: 5.6 months |